natgillin/translations-raw huggingface dataset:
The maximum total surface of lesions (treated in cm2) should not exceed 10 times the body weight (in kg).
4. 10 Preveliko odmerjanje
Overdosing, i. e. application rate of more than twice a day, or extension of the duration of treatment, increases the risk of glucocorticoid systemic effects particularly when administered on extensive lesions.
Preveliko odmerjanje, t. j. pogostejša uporaba kot dvakrat na dan ali podaljšanje zdravljenja, poveča nevarnost glukokortikoidnih sistemskih učinkov, zlasti kadar zdravilo uporabljamo na večjem prizadetem predelu.
Glucocorticosteroid, ATCvet code:
Farmakoterapevtska skupina: glukokortikosteroid, oznaka ATCvet:
3/ 15 6.2 Shelf-life
3/ 15 6. 2 Rok uporabnosti
Shelf-life after first opening of the tube:
Rok uporabnosti po prvem odpiranju vsebnika:
8 weeks.
8 tednov
6.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from such medicinal products
6. 5 Posebni varnostni ukrepi za odstranjevanje neporabljenega zdravila ali odpadnih snovi, ki nastanejo iz teh zdravil
11 PROHIBITION OF SALE, SUPPLY AND/ OR USE
PREPOVED PRODAJE, OSKRBE IN/ ALI UPORABE
The Ministerie van Landbouw, Natuurbeheer en Visserij confirmed that the manufacturing site was authorised under number 324-BVEAK for pharmaceutical products.
The Ministerie van Landbouw, Natuurbeheer en Visserij je potrdilo, da je kraj izdelave registriran pod številko 324- BVEAK za farmacevtske izdelke.
8/ 15 PARTICULARS TO APPEAR ON THE OUTER PACKAGE PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE
PRIMARNI OVOJNINI
Resocortol butyrate 1mg/ g
Resokortol butirat, 1 mg/ g
SPECIAL WARNING(S), IF NECESSARY
POSEBNO( A) OPOZORIL( O) A, ČE JE/ SO POTREBNO( A)
9/ 15 Do not use in dogs with extensive lesions.
9/ 15 Ne uporabljajte pri psih z obsežnimi poškodbami.
The maximum total surface of lesions (treated in cm2) should not exceed 10 times the body weight (in kg).
Največja skupna površina zdravljenih poškodb (v cm2) ne sme biti večja kot 10- kratna telesna masa (v kg).
Month/ Year Once broached, use within 8 weeks
Mesec/ leto Načeto/ odprto zdravilo uporabite v 8 tednih.
10/ 15 PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
10/ 15 PODATKI NA MANJŠIH STIČNIH OVOJNINAH
Resocortol butyrate 1 mg/ g
Resokortol butirat, 1 mg/ g
Month\Year Once broached, use within 8 weeks
Mesec/ leto Načeto/ odprto zdravilo uporabite v 8 tednih.
12/ 15 PACKAGE INSERT
12/ 15 NAVODILO ZA UPORABO
Resocortol butyrate:
Resokortol butirat:
Overdosing, i. e. application rate of more than twice a day, or extension of the duration of treatment, increases the risk of glucocorticoid systemic effects particularly when administered on extensive lesions.
Preveliko odmerjanje, t. j. pogostnejša uporaba kot 2- krat na dan ali podaljšanje zdravljenja, poveča nevarnost glukokortikoidnih sistemskih učinkov, zlasti kadar zdravilo uporabljamo na večjem predelu.
Apply a 1 cm strip (0.2 g) of cream per 10 cm2 of lesion.
Nanesite 1 cm (0, 2 g) kreme na 10 cm2 poškodbe.
Shelf life after first opening of the tube:
Rok uporabnosti po prvem odpiranju vsebnika:
Vaccines work by priming the immune system (the body ’ s natural defences) how to defend itself against diseases.
Cepiva delujejo tako, da imunski sistem (naravne obrambne mehanizme telesa) pripravijo na obrambo proti bolezni.
Purevax FeLV contains genes from the FeLV sub-group A called env and gag which have been inserted into another vector (carrier) virus called canarypox using ‘ recombinant DNA technology’.
Zdravilo Purevax FeLV vsebuje gene virusa FeLV podskupine A, imenovane env in gag, ki so jih s pomočjo „ tehnologije rekombinantne DNA “ vstavili v drug vektorski (prenašalni) virus, imenovan poxvirus kanarčkov.
When a cat is given the vaccine, the immune system recognises the FeLV proteins as ‘ foreign’ and makes antibodies against them.
Kadar mačka prejme cepivo, imunski sistem prepozna beljakovine virusa FeLV kot „ tuje “ in začne proti njim tvoriti protitelesa.
Immunisation against FeLV sub-group A provides full protection against all three sub-groups of the virus:
Cepljenje proti virusu FeLV podskupine A nudi celovito zaščito proti vsem trem podskupinam virusa:
A, B and C.
A, B in C.
Reproduction is authorised provided the source is acknowledged How has Purevax FeLV been studied?
Reproduction is authorised provided the source is acknowledged Kako je bilo zdravilo Purevax FeLV raziskano?
In case of accidental self-injection seek medical advice immediately and show the Package Leaflet or the label to the doctor.
V primeru nenamernega samo- injiciranja se takoj posvetujte z zdravnikom in mu pokažite Navodilo za uporabo ali nalepko na škatli zdravila.
Information on the prescription status of this product may be found on the label/ outer package.
Podatki o statusu predpisovanja tega zdravila so na nalepki/ zunanji ovojnini.
Route of administration
Načina dajanja
Package Size
Pakiranje
FeLV recombinant Canarypox virus (vCP97) ≥ 10 7.2 CCID50 (cell culture infective dose)
FeLV rekombinantni poxvirus kanarčkov (vCP97) ≥ 10 7. 2 CCID50
Box of 10 x 1 bottles.
škatla z 10 x 1 prebodnimi stekleničkami
FeLV recombinant Canarypox virus (vCP97) ≥ 10 7.2 CCID50)
FeLV rekombinantni poxvirus kanarčkov (vCP97) ≥ 10 7. 2 CCID50
Box of 20 x 1 bottles
škatla z 20 x 1 prebodnimi stekleničkami
FeLV recombinant Canarypox virus (vCP97) ≥ 10 7.2 CCID50
FeLV rekombinantni poxvirus kanarčkov (vCP97) ≥ 10 7. 2 CCID50
Box of 50 x 1 bottles
škatla s 50 x 1 prebodnimi stekleničkami
Active substance(s) FeLV recombinant Canarypox virus (vCP97)......... ≥ 10 7.2 CCID50 (cell culture infective dose 50%) For a full list of excipients, see section 6.1.
Rekombinantni poxvirus kanarčkov, ki vsebuje antigen virusa mačje levkemije (vCP97) ≥ 10 7, 2 CCID50 (50% infektivni odmerek za celično kulturo) Celoten seznam pomožnih snovi, glej razdelek 6. 1.
Onset of immunity has been demonstrated 2 weeks after primary vaccination course.
Imunost se razvije dva tedna po prvem cepljenju.
The duration of immunity is one year after the last vaccination.
Žival je imuna eno leto po zadnjem cepljenju.
Use is not recommended during lactation.
Uporaba ni priporočljiva v obdobju laktacije.
Vaccinate only healthy animals..
- Cepite le zdrave živali
It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination..
- Pred cepljenjem je priporočljivo opraviti test za ugotavljanje prisotnosti antigenov za FeLV
Vaccination of FeLV positive cats is of no benefit.
- Cepljenje FeLV pozitivnih mačk ni smiselno.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki daje zdravilo živalim
2 4.6 Adverse reactions (frequency and seriousness)
2 4. 6 Neželeni učinki (pogostnost in resnost)
In exceptional circumstances a hypersensitivity reaction may occur, which may require appropriate symptomatic treatment..
- Izjemoma se lahko pojavi preobčutljivostna reakcija, ki jo je treba ustrezno simptomatično
A temporary small (< 2 cm) nodule may appear at the site of injection which regresses within 1 to 4 weeks..
- Na mestu injiciranja se lahko pojavi manjši vozlič (< 2cm), ki je prehoden in izgine v enem do
Transient lethargy and hyperthermia may occur for 1 day, exceptionally 2 days.
- Lahko se pojavita prehodna letargičnost in povišana temperatura, ki lahko trajata en dan in le
4.7 Use during pregnancy, lactation or lay
4. 7 Uporaba v obdobju brejosti in laktacije
Use is not recommended during lactation.
Cepljenje v obdobju laktacije ni priporočljivo.
Safety and efficacy data are available which demonstrate that this vaccine can be administered the same day but not mixed with Merial adjuvanted vaccines (various combinations of feline viral rhinotracheitis, calicivirosis, panleukopenia and rabies components).
Informacije o varnosti in učinkovitosti cepiva navajajo, da to cepivo lahko dajemo isti dan vendar ne pomešano z Merialovimi adjuviranimi cepivi (različne kombinacije cepiv s komponentami proti virusnemu rinotraheitisu, calicivirozi, panleukopenji in steklini).
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Merial non-adjuvanted vaccine range (various combinations of feline viral rhinotracheitis, calicivirosis, panleukopenia and chlamydiosis components) and/ or administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
Informacije o varnosti in učinkovitosti dovoljujejo sočasno uporabo cepiva z Merialovimi neadjuviranimi cepivi za mačke (več kombinacij mačjih cepiv s komponentami proti virusnemu rinotraheitisu, calicivirozi, panleukopenji in klamidiozi) v isti brizgi in/ ali sočasno uporabo, vendar ne pomešano z Merialovimi adjuviranimi cepivi proti steklini.
4.9 Amounts to be administered and administration route
5. 8 Odmerjanje in način uporabe
Inject by subcutaneous route one 1-ml dose of vaccine according to the following schedule:
V podkožje injicirajte 1 odmerek (1 ml) cepiva po naslednjem razporedu:
first injection: from 8 weeks of age, second injection:
prvi odmerek od osmega tedna starosti dalje, drugi odmerek:
3 to 5 weeks later.
3 do 5 tednov pozneje.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
5. 9 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če so potrebni)
No undesirable effect has been observed after the administration of several doses except those mentioned in the “ Adverse reactions” section.
Po vnosu večkratnih odmerkov cepiva niso opazili nobenih drugih neželenih učinkov razen tistih, navedenih v poglavju » Neželeni učinki «.
The vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A.
Cepni sev je rekombinantni poxvirus kanarčkov, ki izraža env in gag gene FeLV- A.
Under field conditions, only sub-group A is infective and immunisation against sub-group A provides full protection against A, B and C.
V naravi je infektivna le podskupina A in imunizacija proti podskupini A zagotavlja tudi popolno zaščito proti A, B in C.
After inoculation, the virus expresses the protective proteins, but does not replicate in the cat.
Po inokulaciji virus izloča zaščitne proteine, a se v mački ne množi.
ATC vet code:
ATC vet koda:
QI06AD
Q106AD
Salts Water for injections.
Soli Voda za injiciranje
Do not mix with any other vaccine or immunological product except Merial non-adjuvanted vaccine range.
Ne mešajte z nobenim drugim cepivom ali imunološkim izdelkom, razen z Merialovimi neadjuviranimi cepivi.
2 years Use immediately after broaching.
2 leti Uporabite takoj po rekonstituciji.
Store and transport at 2°C – 8°C (in a refrigerator), protected from light.
Zaščitite pred svetlobo.
Nature of primary packaging elements:. type I glass bottle.. closure: butyl elastomer closure, sealed with an aluminium cap
Opis sestavnih delov vsebnika:. steklenička iz stekla tipa I.. zaporka: butilelastomerna zaporka, zapečatena z aluminijastim pokrovčkom
1 dose bottle of suspension:. box of 10 x 1 bottles.. box of 20 x 1 bottles.. box of 50 x 1 bottles.
Steklenička z 1 odmerkom liofilizata in steklenička z 1 ml vehikla:. škatla z 10 x 1 steklenička. škatla z 20 x 1 steklenička. škatla s 50 x 1 steklenička
5 ANNEX II
5 ANNEX II
6 A.
6 A
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
UČINKOVIN) IN IMETNIK DOVOLJENJA ODGOVOREN ZA SPROSTITEV SERIJE
Name and address of the manufacturer of the biological active substance(s) MERIAL Laboratoire Porte des Alpes Rue de l’ Aviation F-69800 SAINT PRIEST FRANCE
MERIAL Laboratoire Porte des Alpes Rue de l’ Aviation F- 69800 SAINT PRIEST FRANCIJA
MERIAL Laboratoire Lyon Gerland 254, rue Marcel Mérieux F-69007 Lyon FRANCE
MERIAL Laboratoire de Lyon Gerland 254, rue, Marcel Mérieux F- 69007 LYON FRANCIJA
MERIAL Laboratoire Porte des Alpes Rue de l’ Aviation F-69800 SAINT PRIEST FRANCE
MERIAL Laboratoire Porte des Alpes Rue de l’ Aviation F- 69800 SAINT PRIEST FRANCIJA
9 PARTICULARS TO APPEAR ON THE OUTER PACKAGE {NATURE/ TYPE}
9 PODATKI NA ZUNANJI OVOJNINI {VRSTA/ TIP}
FeLV recombinant Canarypox virus (vCP97)......... ≥ 10 7.2 CCID50
Rekombinantni poxvirus kanarčkov, ki vsebuje antigen virusa mačje levkemije (vCP97) ≥ 10 7, 2 CCID50
1-ml suspension (10 bottles) 20 doses:
1 ml suspenzije (10 stekleničk) 20 odmerkov:
1-ml suspension (20 bottles) 50 doses:
1 ml suspenzije (20 stekleničk) 50 odmerkov:
1-ml suspension (50 bottles)
1 ml suspenzije (50 stekleničk)
Subcutaneous use.
Cepite subkutano.
EXP (dd/ mm/ yy) Use immediately after broaching
EXP {dan/ mesec/ leto} Uporabite takoj po rekonstituciji.
Read the package leaflet before use.
Glej točko 9.
MERIAL 29 avenue Tony Garnier F-69007 LYON FRANCE
Imetnik dovoljenja za promet z zdravilom MERIAL 29 avenue Tony Garnier F- 69007 LYON FRANCIJA
EU/ 2/ 00/ 019/ 005 10 doses:
EU/ 2/ 00/ 019/ 005 EU/ 2/ 00/ 019/ 006 EU/ 2/ 00/ 019/ 007
1-ml suspension (10 bottles) EU/ 2/ 00/ 019/ 006 20 doses:
1 ml suspenzije (10 stekleničk) 20 odmerkov:
1-ml suspension (20 bottles) EU/ 2/ 00/ 019/ 007 50 doses:
1 ml suspenzije (20 stekleničk) 50 odmerkov:
11 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
11 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Purevax FeLV suspension for injection
Purevax FeLV suspenzija za injiciranje
Subcutaneous use
Cepite subkutano.
13 PACKAGE LEAFLET Purevax FeLV Suspension for injection
13 NAVODILO ZA UPORABO Purevax FeLV Suspenzija za injiciranje
Marketing authorisation holder MERIAL 29 avenue Tony Garnier F-69007 LYON FRANCE
Imetnik dovoljenja za promet z zdravilom MERIAL 29 avenue Tony Garnier F- 69007 LYON FRANCIJA
Manufacturing authorisation holder responsible for batch release MERIAL Laboratoire Porte des Alpes Rue de l’ Aviation F-69800 SAINT PRIEST FRANCE
Imetnik dovoljenja proizvodnjo, odgovoren za sprostitev serije MERIAL Laboratoire Porte des Alpes Rue de l’ Aviation F- 69800 SAINT PRIEST FRANCIJA
FeLV recombinant Canarypox virus (vCP97)......... ≥ 10 7.2 CCID50 (cell culture infective dose 50%)
Rekombinantni poxvirus kanarčkov, ki vsebuje antigen virusa mačje levkemije( vCP97) ≥ 10 7. 2 CCID50 (50% infektivni odmerek v celični kulturi)
Onset of immunity has been demonstrated 2 weeks after primary vaccination course.
Imununost je bila dokazana 2 tedna po prvem cepljenju.
A temporary small (< 2 cm) nodule may appear at the site of injection which regresses within 1 to 4 weeks.
- V izjemnih primerih se lahko pojavi preobčutljivostna reakcija, ki jo je treba ustrezno
Transient lethargy and hyperthermia may occur for 1 day, exceptionally 2 days.
simptomatično zdraviti
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
- Na mestu injiciranja se lahko pojavi manjši vozlič (< 2cm), ki je prehoden in izgine v enem do
14 7.
14
TARGET SPECIES
- Lahko se pojavita prehodna letargičnost in povišana temperatura, ki trajata en dan in le
Cats
izjemoma dva dni.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
CILJNA ŽIVALSKA VRSTA
Basic vaccination:
Mačke
first injection: from 8 weeks of age, second injection:
ODMERJANJE ZA VSAKO ŽIVALSKO VRSTO
3 to 5 weeks later.
3 do 5 tednov pozneje;
annual
enkrat letno.
Shake well before use.
Po rekonstituciji dobro pretresite.
Keep out of the reach and sight of children..
- Zdravilo shranjujte nedosegljivo otrokom.
Store and transport at 2°C – 8°C (in a refrigerator), protected from light.
Shranjujte pri temperaturi 2 °C – 8 °C (v hladilniku), zaščiteno pred svetlobo.
Do not freeze..
Cepivo ne sme
Use immediately after broaching..
- Uporabite takoj po odprtju.
Do not use after the expiry date stated on the label.
- Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na nalepki.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Če vam je bil ta proizvod nenamerno injiciran, se takoj posvetujte z zdravnikom in mu pokažite navodilo za uporabo.
Do not use in pregnant animals.
Ne cepite breje živali.
Use is not recommended during lactation.
Ne uporabite pri živalih v obdobju laktacije.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Merial non-adjuvanted vaccine range (various combinations of feline viral rhinotracheitis, calicivirosis, panleukopenia and chlamydiosis components) and/ or administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
15 Informacije o varnosti in učinkovitosti dovoljujejo sočasno uporabo cepiva z Merialovimi neadjuviranimi cepivi za mačke (več kombinacij mačjih cepiv s komponentami proti virusnemu rinotraheitisu, calicivirozi, panleukopenji in klamidiozi) v isti brizgi in/ ali sočasno uporabo, vendar ne pomešano z Merialovimi adjuviranimi cepivi proti steklini.
15 No undesirable effect has been observed after the administration of several doses except those mentioned in the “ Adverse reactions” section.
Po vnosu večkratnih odmerkov cepiva niso opazili nobenih drugih učinkov razen tistih, navedenih v poglavju » Neželeni učinki «.
Under field conditions, only sub-group A is infective and immunisation against sub-group A provides full protection against A, B and C.
V naravi je infektivna le podskupina A. in imunizacija proti podskupini A zagotavlja tudi popolno zaščito proti A, B in C.
After inoculation, the virus expresses the protective proteins, but does not replicate in the cat.
Po inokulaciji virus izraža zaščitne proteine, vendar se v mački ne množi.
Box of 10 x 1 bottles.
Škatla z 10 x 1 stekleničko.
Box of 20 x 1 bottles.
Škatla z 20 x 1 stekleničko.
Box of 50 x 1 bottles.
Škatla z 50 x 1 stekleničko.
To be supplied only on veterinary prescription.
Zdravilo se izda le na recept.
EPAR summary for the public This document is a summary of the European Public Assessment Report.
Povzetek EPAR za javnost Ta dokument je povzetek Evropskega javnega poročila o oceni zdravila (EPAR).
Purevax RC is a vaccine containing the following active substances: • attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains).
Zdravilo Purevax RC je cepivo, ki vsebuje naslednje zdravilne učinkovine: • atenuirani (oslabljeni) herpesvirus rinotraheitisa mačk (sev FHV F2), • inaktivirane (uničene) antigene kalicivirusa mačk (seva FCV 431 in G1).
Purevax RC is used to vaccinate cats from the age of 8 weeks against the following diseases: • feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus), • feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus).
Zdravilo Purevax RC se uporablja za cepljenje mačk od 8. tedna starosti naprej proti naslednjima boleznima: • virusnemu rinotraheitisu mačk (gripi podobni bolezni, ki jo povzroča herpesvirus), • kalicivirozi mačk (gripi podobni bolezni z vnetjem ust, ki jo povzroča kalicivirus).
When a cat is given the vaccine, the immune system recognises the weakened or killed viruses as ‘ foreign’ and makes antibodies against them.
Ko mačko cepimo, imunski sistem prepozna oslabljene ali uničene viruse kot „ tuje “ in proti njim tvori protitelesa.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged How has Purevax RC been studied?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged Kako je bilo zdravilo Purevax RC raziskano?
In the field, the studies of Purevax RC looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination (only one injection).
V študijah zdravila Purevax RC na terenu so preverili osnovni cepilni program (2 injekciji 3– 4 tedne narazen) in obnovitveno cepljenje (samo ena injekcija).
Invented Strength
Izmišljen o ime
Package
Ciljna živalska vrsta
species administration
Vsebina (koncentracija)
(concentration) size
Velikost pakiranja
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose
Atenuirani herpes virus rinotraheitisa mačk (sev
Lyophilisate and solvent for suspension for injection
Liofilizat in vehikel za
Subcutaneous use
1 odmerek liofilizata
Type I glass bottle closed with a butyl elastomer closure and sealed with an aluminium cap
iz stekla tipa 1, zaprta z gumijastim zamaškom in zaščitena z aluminijasto zaporko
10 bottles of 1 dose (lyophilisate) and 10 bottles of 1ml (solvent)
(liofilizata) in 10 stekleničk po 1 ml (vehikla)
1 dose of lyophilis ate and 1ml of solvent
in 1 ml vehikla
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2): ≥ 104, 9 CCID50 na odmerek Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in sev FCV G1): ≥ 2, 0 enot v testu ELISA na odmerek
50 bottles of 1 dose (lyophilisate) and 50 bottles of 1ml (solvent)
50 stekleničk z 1 odmerkom (liofilizata) in 50 stekleničk po 1 ml (vehikla)
1 dose of lyophilis ate and 1ml of solvent
1 odmerek liofilizata in 1 ml vehikla
Purevax RCCh is a vaccine containing the following active substances: • attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains), • attenuated Chlamydophila felis (905 strain).
Zdravilo Purevax RCCh je cepivo, ki vsebuje naslednje zdravilne učinkovine: • atenuirani (oslabljeni) herpesvirus rinotraheitisa mačk (sev FHV F2), • inaktivirane (uničene) antigene kalicivirusa mačk (seva FCV 431 in G1), • atenuirano bakterijo Chlamydophila felis (sev 905).
Purevax RCCh is used to vaccinate cats from the age of 8 weeks against the following diseases: • feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus), • feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus), • chlamydiosis (a flu-like illness caused by the bacterium C. felis).
Zdravilo Purevax RCCh se uporablja za cepljenje mačk od 8. tedna starosti naprej proti naslednjim boleznim: • virusnemu rinotraheitisu mačk (gripi podobni bolezni, ki jo povzroča herpesvirus), • kalicivirozi mačk (gripi podobni bolezni z vnetjem ust, ki jo povzroča kalicivirus), • klamidiozi (gripi podobni bolezni, ki jo povzroča bakterija C. felis).
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged How does Purevax RCCh work?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged Kako zdravilo Purevax RCCh deluje?
When a cat is given the vaccine, the immune system recognises the weakened or killed viruses and the weakened bacteria as ‘ foreign’ and makes antibodies against them.
Ko mačko cepimo, imunski sistem prepozna oslabljene ali uničene viruse in oslabljene bakterije kot „ tuje “ ter proti njim tvori protitelesa.
In the field, the studies of Purevax RCCh looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination (only one injection).
V študijah zdravila Purevax RCCh na terenu so preverili osnovni cepilni program (2 injekciji 3– 4 tedne narazen) in obnovitveno cepljenje (samo ena injekcija).
Package
Ovojnina
size
Velikost pakiranja